1 P. Gisondi, A. Conti, G. Galdo, S. Piaserico, C. De Simone, G. Girolomoni. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br. J. Dermatol. 168 (2013) 1124-1127. doi:10.1111/bjd.12235.
2 A. Caraceni, G. Hanks, S. Kaasa, M.I. Bennett, C. Brunelli, N. Cherny, O. Dale, De F. Conno, M. Fallon, M. Hanna, Haugen, D.F. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 13 (2012) e58-68. doi:10.1016/S1470-2045(12)70040-2.
3 J.L. Poulsen, C. Brock, A.E. Olesen, M. Nilsson, A.M. Drewes. Evolving paradigms in the treatment of opioid-induced bowel dysfunction. Therap. Adv. Gastroenterol. 8 (2015) 360-372. doi:10.1177/1756283X15589526.
4 B. Morlion, Clemens, K.E., Dunlop, W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. Clin. Drug. Investig. 35 (2015) 1-11. doi:10.1007/s40261-014-0254-6.
5 M. Lazzari, M.T. Greco, C. Marcassa, S. Finocchi, C. Caldarulo, Corli, O. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naive cancer patients: a propensity analysis. Drug. Des. Devel. Ther. 9 (2015) 5863-5872. doi:10.2147/DDDT.S92998.
6 Camilleri, M. Opioid-induced constipation: challenges and therapeutic opportunities. Am. J. Gastroenterol. 106 (2011) 835-842. doi:10.1038/ajg.2011.30.
7 S. Wirz, M. Wittmann, M. Schenk, A. Schroeck, N. Schaefer, M. Mueller, J. Standop, N. Kloecker, J. Nadstawek. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur. J. Pain 13 (2009) 737–743. doi: 10.1016/j.ejpain.2008.09.005.
8 S.F. Cook, L. Lanza, X. Zhou, C.T. Sweeney, D. Goss, K. Hollis, A.W. Mangel, Fehnel, S.E. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther 27 (2008) 1224–1232. doi: 10.1111/j.1365-2036.2008.03689.x.
9 T.J. Bell, S.J. Panchal, C. Miaskowski, S.C. Bolge, T. Milanova, Williamson, R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 10 (2009) 35–42. doi: 10.1111/j.1526-4637.2008.00495.x
10 M. Yotoku, A. Nakanishi, M. Kanematsu, N. Sakaguchi, N. Hashimoto, F. Koyama, S. Yamaguchi, K. Ikeda, Konishi, H. and Hirotani, Y. Reduction of opioid side effects by prophylactic measures of palliative care team may result in improved quality of life. J. Palliat. Med. 13 (2010) 401–406, doi: 10.1089/jpm.2009.0355.
11 G. Rosti, A. Gatti, A. Costantini, A.F. Sabato, Zucco, F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur. Rev. Med. Pharmacol. Sci. 14 (2010) 1045–1050.
12 A.K. Tuteja, J. Biskupiak, G.J. Stoddard, Lipman, A.G. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Newrogastroenterol. Motil. 22 (2010) 424-430. doi: 10.1111/j.1365-2982.2009.01458.x.
13 Clinical Guidelines for Gastrointestinal Symptoms in Cancer Patients ver. 2017
14 M. Ishihara, H. Ikesue, H. Matsunaga, K. Suemaru, K. Kitaichi, K. Suetsugu, R. Oishi, T. Sendo, H. Araki, Itoh, Y. Japanese study group for the relief of opioid-induced gastrointestinal dysfunction. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 28 (2012) 373-81. doi: 10.1097/ajp.0b013e318237d626.
15 M. Camilleri, D.A. Drossman, G. Becker, L.R. Webster, A.N. Davies, Mawe, G.M. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol. Motil. 26 (2014) 1386-1395. doi:10.1111/nmo.12417.
16 Song. X, Wang. D, Qu. X, Dong. N, Teng. S. A meta-analysis of naldemedine for the treatment of opioid-iduced constipation. Expert Rev Clin Pharmacol. 12 (2019) 121-128. doi: 10.1080/17512433.2019.1570845.
17 K. Fukumura, T. Yokota, Y. Baba, J.C. Arjona Ferreira. Phase 1, Randomized, double-blind, placebo-controlled studies on the safety, tolerability, and pharmacokinetics of naldemedine in healthy volunteers. Clin. Pharmacol. Drug. Dev. 7 (2017) 474-483. doi:10.1002/cpdd.387.
18 L.R. Webster, T. Yamada, J.C. Arjona Ferreira. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 18 (2017) 2350-2360. doi:10.1093/pm/pnw325.
19 N. Katakami, T. Harada, T. Murata, K. Shinozaki, M. Tsutsumi, T. Yokota, M. Arai, Y. Tada, M. Narabayashi, Boku, N. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann. Oncol. 29 (2018) 1461-1467. doi: 10.1093/annonc/mdy118.
20 A. Nakajima, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomized, double-blinded, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 3 (2018) 537-547. doi: 10.1016/S2468-1253
21 Mokhtare, M. et al. Reliability and validity of the Persian version of patient assessment of constipation- quality of life (JPAC-QOL) questionnaire. Gastroenterol Hepatol Bed Bench. 10 (2017) 289-294.
22 Ishihara, M. et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 28 (2012) 373-381. doi: 10.1097/ajp.0b013e318237d626.
23 A.J. Hatswell, Vegter, S. Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3 L and JPAC-QOL. Health Econ. Rev. 6 (2016) 14-…. doi: 10.1186/s13561-016-0091-9
24 C.L. Miles, D. Fellowes, Goodman, M.L. and Wilkinson, S. Laxatives for the management of constipation in palliative patients. Cochrane Database Syst. Rev. 4 (2006) CD003448. doi: 10.1002/14651858.cd003448.
25 Y. Agra, SacristáA. n, GonzáM. lez, M. Ferrari, PortuguéA. s, Calvo, M.J. Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J. Pain Symptom Manage. 15 (1998) 1-7. doi: 10.1016/S0885-3924(97)00276-5.